Core Insights - Teleflex has parted ways with CEO Liam Kelly, appointing Stuart Randle as interim president and CEO while searching for a permanent replacement [3][8] - The leadership change is part of a transformation strategy following the announcement of divesting three business units for approximately $2 billion [5][8] - Teleflex has revised its revenue guidance for 2025 to $3.27 billion to $3.28 billion, down from a previous estimate of $3.31 billion to $3.32 billion, citing softer demand for certain medical devices [7][8] Leadership Changes - Liam Kelly, who became CEO in 2018, has left the company without a permanent successor [3] - Stuart Randle, a board member since 2009 and former CEO of Ivenix, has been appointed as interim president and CEO [4][5] - Stephen Klasko has taken over as chairman of the board following Kelly's departure [3] Business Strategy - Teleflex is in the process of closing the $1.5 billion sale of its OEM business and the $530 million sale of its acute care and interventional urology units [5][6] - The divestitures will allow Teleflex to focus on its vascular access, interventional, and surgical businesses [6] Financial Outlook - The company expects a revenue reduction of just over 1% at the midpoint due to lower-than-expected demand for intra-aortic balloon pumps and catheters in the U.S. and Asia [7] - The revised revenue guidance reflects challenges in the OEM business and delays in purchase orders [7]

Leadership Changes - Stuart Randle has been appointed as Interim President and CEO of Teleflex, succeeding Liam Kelly, who has departed from the company [1] - Dr. Stephen Klasko has been appointed as Chairman of the Board [1][2] - The Board has engaged Spencer Stuart to assist in the search for a permanent CEO [2] Business Strategy and Focus - Teleflex is transitioning to a more focused, higher-growth organization following the announced sale of its Acute Care, Interventional Urology, and OEM businesses [3] - The leadership transition is aimed at positioning the company for future growth in core critical care and high-acuity hospital markets [3] Financial Performance Update - The company expects full year 2025 revenue to be between $3.270 billion and $3.278 billion, a decrease from previous guidance of $3.305 billion to $3.320 billion [4] - The revenue reduction is primarily due to lower than expected demand for intra-aortic balloon pumps and catheters in the U.S. and Asia, as well as delays in OEM purchase orders [5] Future Reporting - Teleflex plans to report its full fourth quarter and full year 2025 financial results in late February or early March 2026 [7]

Shot of Corridor in Working Data Center Full of Rack Servers and Supercomputers with Cloud Storage Advantages Icon Visualization.gettyToday I have a sweet dividend “double shot” for you: The first? A 2.8% payout set to grow thanks to AI—and take the stock price up with it.The second gives you high payouts now, in the form of a monthly-paid 7.8% divvie that also looks set to head higher.Both of these tickers are cheap. In fact, they (and the sector they’re in) could very well be the last bargains on the boar ...

Core Thesis - Teleflex Incorporated (TFX) is positioned for a strategic turnaround after two decades of underwhelming returns due to poor capital allocation, with a current market capitalization of $3.5 billion and a share price of $114.41 as of December 1st [2][3]. Business Segmentation - TFX specializes in consumables for hospitals and surgical providers, focusing on vascular and urological markets, with secondary exposure to surgical, acute care, and contract manufacturing [2]. - The company produces a wide range of single-use products, including catheters, stents, guidewires, pumps, and closures [2]. Spin-off Strategy - In February 2025, TFX announced a spin-off of its urology, acute care, and OEM businesses into a stand-alone public company ("NewCo"), while retaining higher-growth, higher-margin vascular/interventional and surgical franchises in "RemainCo" [3]. - This separation is expected to unlock significant shareholder value by allowing each entity to pursue independent strategies, with NewCo focusing on cost optimization and cash generation, and RemainCo accelerating innovation in vascular interventions [3]. Financial Performance - Pro forma, TFX generates $3.5 billion in sales and $1 billion in EBITDA, with NewCo accounting for $1.4 billion in sales and RemainCo for $2.1 billion [4]. - TFX currently trades at a 10% free cash flow yield, which is below peer SMID-cap medical device valuations, indicating a potential upside of 30–45%, and over 100% if either entity is sold at strategic multiples [4]. Investment Opportunity - The anticipated spin-off or sale within six months presents an attractive asymmetric risk/reward profile, combining immediate free cash flow yield with significant strategic upside for both NewCo and RemainCo [5]. - This makes TFX a compelling investment opportunity in the med-tech space, similar to the bullish thesis on Medtronic plc's spin-off strategy [6].

Company Overview - Teleflex Incorporated is a $3.5 billion medical device company specializing in consumables for hospitals and surgical providers, with its largest markets in vascular and urological sectors, and secondary exposure to surgical, acute care, and contract manufacturing [2] - The company produces thousands of single-use products, including catheters, stents, guidewires, pumps, and closures [2] Strategic Developments - In February 2025, Teleflex announced a spin-off of its urology, acute care, and OEM businesses into a stand-alone public company ("NewCo"), leaving the higher-growth, higher-margin vascular/interventional and surgical franchises in TFX "RemainCo" [3] - This separation is expected to unlock significant shareholder value by allowing each business to pursue independent strategies and capital allocation [3] - NewCo is focusing on cost optimization and cash generation, while RemainCo is set to accelerate innovation in vascular interventions, including the recently acquired Biotronik business [3] Financial Performance - Pro forma, Teleflex generates $3.5 billion in sales and $1 billion in EBITDA, with NewCo at $1.4 billion and RemainCo at $2.1 billion [4] - Teleflex trades at a 10% free cash flow yield, below peer SMID-cap medical device valuations, implying 30–45% upside, with the potential for over 100% upside if RemainCo or NewCo were sold at strategic multiples [4] Investment Opportunity - With the spin or sale likely within six months, Teleflex offers an attractive asymmetric risk/reward profile, combining immediate free cash flow yield with significant strategic upside for both NewCo and RemainCo [5] - This makes Teleflex a compelling investment opportunity in the med-tech space [5]

Core Insights - Cullen Capital Management's "SCCM Value Equity Strategy" reported a gross return of 6.9% and a net return of 6.8% for Q3 2025, outperforming the Russell 1000 Value's 5.3% and underperforming the S&P 500's 8.1% during the same period [1] - Year-to-date, the strategy achieved a gross return of 13.0%, compared to Russell 1000 Value's 11.7% and S&P 500's 14.8% [1] Company Overview - Becton, Dickinson and Company (NYSE: BDX) is a global medical technology company that develops and manufactures a wide range of medical supplies, devices, laboratory equipment, and diagnostic products [2][3] - The company has three main segments: BD Medical (50% of 2024 sales), BD Life Sciences (26%), and BD Interventional (24%) [3] - BD Medical focuses on medication delivery devices, holding over 80% market share in US hospital syringes, making it the largest manufacturer of syringes globally [3] Stock Performance - Becton, Dickinson and Company's stock had a one-month return of 2.24% but lost 13.52% over the last 52 weeks, closing at $192.33 per share on November 18, 2025, with a market capitalization of $55.127 billion [2]

Group 1 - Boston Scientific Corporation (NYSE:BSX) is recognized as one of the best long-term stocks to buy, with UBS maintaining a Buy rating and raising the price target to $140 from $135 following strong quarterly results [1] - The company reported net revenue of $5,065 million for Q3, reflecting a 15.3% year-over-year organic growth, and adjusted earnings per share of $0.75, exceeding the consensus estimate of $0.71 [2] - Boston Scientific has increased its full-year 2025 outlook, now projecting approximately 20% growth and adjusted EPS of $3.02-$3.04, an increase from previous estimates [2] Group 2 - The FARAPULSE product line experienced approximately 63% organic worldwide expansion, with US growth improving by 40 percentage points on a comp-adjusted basis [3] - The WATCHMAN device achieved 35% organic sales growth for the fifth consecutive quarter, indicating increasing product acceptance [3] Group 3 - Boston Scientific Corporation is a global leader in manufacturing medical devices, including stents, brain stimulation systems, heart monitors, and catheters [4]

Core Insights - Fiduciary Management Inc. (FMI) reported a strong performance in the third quarter of 2025, with major stock indices such as the Russell 2000 and S&P 500 gaining 12.39% and 8.12% respectively, driven by a Federal Reserve rate cut and enthusiasm for AI and technology stocks [1] - FMI's investment strategy focuses on idiosyncratic dislocations, prioritizing business quality, balance sheet strength, and valuation while maintaining downside protection [1] Company Overview: Becton, Dickinson and Company (NYSE:BDX) - Becton, Dickinson and Company is a leading healthcare company specializing in medical supplies and devices, with a market capitalization of $54.201 billion and a share price of $189.03 as of October 21, 2025 [2] - The company experienced a one-month return of 1.70% but faced a significant decline of 21.33% over the past 52 weeks [2] Investment Thesis on Becton, Dickinson and Company - FMI views Becton, Dickinson and Company as a quality business with a strong competitive position in an oligopoly market, focusing on low-cost medical essentials [3] - The management's strategy aims for over 5% annual organic revenue growth and margin expansion, with a significant portion of revenue being recurring post-separation of its biosciences and diagnostics solutions business in 2026 [3] - The company's manufacturing scale and durable business model driven by healthcare utilization provide a competitive advantage, making its current valuation attractive given its defensive attributes and growth potential [3]

Core Insights - Boston Scientific Corporation (NYSE:BSX) is recognized as one of the top medical device stocks to invest in, with TD Cowen reaffirming a Buy rating and a price target of $115 on October 10 [1] - The recent analyst visit to Boston Scientific's headquarters reinforced confidence in the company's outlook, particularly in the context of its latest investor day [1] Group 1: Company Performance and Outlook - Significant advancements were noted in pulsed field ablation (PFA) technology during the analyst visit, with feedback suggesting a "very compelling" outlook for Boston Scientific despite increasing market competition [2] - CEO Mike Mahoney provided thoughtful responses to growth-related inquiries, emphasizing category leadership as a strategy for achieving success in the market [2] Group 2: Company Profile - Boston Scientific Corporation is a global leader in manufacturing medical devices, including stents, brain stimulation systems, heart monitors, and catheters [3]

Core Insights - Nordson Corporation (NDSN) has divested its design and development contract manufacturing business units to Quasar Medical, with financial terms undisclosed [1][8] - Following the announcement, Nordson's shares fell by 1.1%, closing at $222.70 [1] Business Operations - Nordson Medical's contract manufacturing businesses, located in Galway, Ireland, and Tecate, Mexico, provide comprehensive solutions for complex interventional devices in the medical industry [2] - The Galway facility will now serve as Quasar Medical's innovation center for advanced medical device manufacturing processes, while the Tecate facility will function as a manufacturing hub for packaging, coating, molding, and automated processes [3] Strategic Alignment - This divestment aligns with Nordson's business transformation strategy aimed at unlocking shareholder value by focusing on core operations and optimizing its Medical and Fluid Solutions portfolio [4] - The divestiture allows Nordson to strengthen its medical component offerings, which include cannulas, catheters, medical balloons, and fluid management solutions [4] Market Performance - Nordson has a market capitalization of $12.5 billion and currently holds a Zacks Rank 2 (Buy) [5] - The company is experiencing strong momentum in its Advanced Technology Solutions segment, driven by customer demand in nonwovens, packaging, consumer non-durable, and optical sensors product lines [5] - Over the past month, Nordson's shares have increased by 4.8%, outperforming the industry growth of 2.4% [6] - The Zacks Consensus Estimate for Nordson's fiscal 2025 earnings is projected at $10.07 per share, reflecting a 0.4% increase from the previous estimate [6]